Long-term bone health in glucocorticoid-treated children with rheumatic diseases

Area of Science:

• Pediatric Rheumatology
• Pediatric Endocrinology
• Pediatric Orthopedics

Background:

• Glucocorticoids (GC) are a primary treatment for pediatric rheumatic diseases.
• Recent studies indicate increased skeletal vulnerability in these children, including fractures and reduced bone mineral density (BMD).
• Vertebral fractures are common, with annual incidence rates of 4-6% in newly diagnosed patients and prevalence of 7-28% in long-term patients.

Purpose of the Study:

• To review the skeletal risks associated with glucocorticoid treatment in pediatric rheumatic diseases.
• To highlight the incidence and characteristics of fractures in this population.
• To discuss factors influencing bone health and suggest areas for future research.

Main Methods:

• Literature review of recent studies on bone health in pediatric rheumatic diseases.
• Analysis of fracture incidence, prevalence, and morphology.
• Evaluation of risk factors including disease severity, GC dose, BMD, and Vitamin D status.

Main Results:

• Vertebral fractures are often asymptomatic, thoracic, and mild in morphology.
• Systemic diseases like SLE and JDM are associated with higher fracture risk.
• Neither BMD nor GC dose reliably predict fracture risk.
• Long-bone fractures (forearm, wrist) occur but do not predict vertebral fractures.
• Bone mass accrual is often suboptimal, though steroid-sparing agents may mitigate effects.
• Vitamin D insufficiency requires ongoing monitoring.

Conclusions:

• Children with rheumatic diseases on GC therapy are at high risk for skeletal complications.
• Current predictors like BMD and GC dose are insufficient for risk assessment.
• Further research is needed to understand and mitigate bone health risks in this pediatric population.